History
Syntopix is a spin-out Company from the world renowned Skin Research Centre at the University of Leeds. Formed in 2003, Syntopix is based on the leading research of husband and wife team Dr Jon Cove and Dr Anne Eady, both respected microbiologists. Their academic work focused on the microbiology of skin, antibiotic resistance in skin bacteria and Staphylococcus aureus as well as the pathobiology of acne and eczema.
The science underpinning the Company was initially funded with £483,000 from the Wellcome Trust, with further rounds of funding (totaling £720,000) from the then Techtran Group, the Viking Fund and the White Rose Seedcorn Fund. This has enabled Syntopix to build a strong management team (see Directors), recruit new scientific staff, extend its disease targets, relocate to new premises and continue to expand its patent portfolio to support pre-clinical evaluation of its lead combinations.
Recent News
23/08/2010 07:00
AGREEMENT WITH GLOBAL CONSUMER PRODUCTS COMPANY
Syntopix signs an exclusive agreement with a world leading health and personal care brands company.
22/06/2010 07:00
Syntopix welcomes a new board member with Mike Townend joining as Non-executive Director
22/04/2009 13:13
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126